Moderna

(NASDAQ: MRNA)
Health Care  |  Biotechnology
160.43 -0.95 -0.59%
Stock Price | May 17, 2021, 4 p.m.
0 Followers
Bid: 155.05
Ask: 165.0
Prev. Close: 161.38
52 Week Low: 46.1301
52 Week High: 189.26
PE Ratio: 131.203252
Dividend Yield: %

Company Summary

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 24 mRNA development programs as of early 2021, with 13 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Read more Read less

Recently Viewed Tickers